Browse by Poster Author

Skip to main content

iwCLL 2025 Main banner

iwCLL X / Twitter

Browse by Poster Author

Type here to filter the list

All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Y
Yagci, Munci

Gazi University Medical Faculty
1438 - Central Nervous System Involvement in Chronic Lymphocytic Leukemia: An International Retrospective Study by ERIC, the European Research Initiative on CLL
Munci Yagci
Favorite
Yakoub-Agha, Ibrahim

CHU de Lille
1507 - Allogeneic stem cell transplantation is effective after pathway inhibitor treatments in CLL – a retrospective study on behalf of the Chronic Malignancies Working Party of EBMT
Ibrahim Yakoub-Agha
Favorite
Yáñez, Lucrecia

Hospital Universitario Marqués de Valdecilla
1004 - Ubiquitin-like post-translational modifications may modulate the pathogenesis of chronic lymphocytic leukemia mediated by RRAS2
Lucrecia Yáñez
Favorite
1106 - Genomic characterization of chronic lymphocytic leukemia patients with TP53 alterations from a spanish real-world cohort treated with targeted agents
Lucrecia Yáñez
Favorite
1302 - Pevonedistat Enhances the Cytotoxic Effect of Rohinitib on B Cells of Chronic Lymphocytic Leukemia
Lucrecia Yáñez
Favorite
1306 - Distinctive Features in NF-kB Regulation Favor a Synergistic Action of Pevonedistat and Laduviglusib on B Cells of Chronic Lymphocytic Leukemia
Lucrecia Yáñez
Favorite
Yang, Dan

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
1005 - hnRNPU regulates alternative splicing of Cav1.2 calcium channel: implications in ibrutinib-associated ventricular arrhythmia
Dan Yang
Favorite
1204 - EGR2 Hotspot Mutations Drive BTKi Resistance in Chronic Lymphocytic Leukemia via CD27-CD70 Interaction-Mediated T-Cell Exhaustion
Dan Yang
Favorite
Yang, Dongyun

City of Hope
1717 - MVA-based GEO-CM04S1 vaccine results in improved cellular immune response in patients with chronic lymphocytic leukemia (CLL) compared with mRNA-based vaccine: initial results of a Phase II randomized study
Dongyun Yang
Favorite
Yang, Jing

Merck & Co., Inc.
1509 - Nemtabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Cohort J of the Phase 2 BELLWAVE-003 Study
Jing Yang
Favorite
Yang, Keri

BeOne Medicines Ltd., USA
1436 - Real-World Treatment Utilization Patterns, Discontinuation and Healthcare Resource Utilization of First-Line (1L) Bruton Tyrosine Kinase Inhibitor (BTKi) Therapy in Chronic Lymphocytic Leukemia (CLL): Age-Related Disparity
Keri Yang
Favorite
1505 - A Meta-Analysis Investigating Response Rates of Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B-Cell Lymphomas
Keri Yang
Favorite
1528 - Estimating the Cardiac Deaths Associated with Treating Chronic Lymphocytic Leukemia with Ibrutinib versus Zanubrutinib in the United States
Keri Yang
Favorite
1908 - Number Needed to Treat Analyses of Zanubrutinib vs Acalabrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia
Keri Yang
Favorite
1909 - A Network Meta-Analysis (NMA) of Efficacy of Zanubrutinib versus Fixed-Duration Acalabrutinib Plus Venetoclax in Treatment-naïve (TN) Chronic Lymphocytic Leukemia (CLL)
Keri Yang
Favorite
1910 - Comparative Efficacy of Zanubrutinib (ZANU) versus Fixed-Duration Acalabrutinib Plus Venetoclax (AV) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL): A Matching-Adjusted Indirect Comparison (MAIC)
Keri Yang
Favorite
1911 - Prospective Patient Preference Study for Chronic Lymphocytic Leukemia (CLL) Treatment Attributes Impacting Patient Shared-Decision Making
Keri Yang
Favorite
Yang, Wei

Department of Hematology Shengjing Hospital of China Medical University
1218 - CD11c: A Promising Indicator for Zanubrutinib Efficacy Evaluation in High-Risk CLL
Wei Yang
Favorite
Yang, Yilian

Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University
1710 - A nomogram for survival prediction based on socioeconomic factors in patients with chronic lymphocytic leukemia: an analysis of SEER database
Yilian Yang
Favorite
Yan, XiaoJie

Feinstein Institutes for Medical Research
1021 - Normal B Cells in MBL Show Abnormal Transcriptomic and Subset Distributions Compared to Healthy Donors: Evidence for Follicular Maturation in IGHV-Mutated MBL and Extrafollicular Maturation in IGHV-Unmutated MBL
XiaoJie Yan
Favorite
1208 - Selectively targeting foreign antigen to surface membrane IgD leads to enhanced T-cell activation in patients with CLL and normal people
XiaoJie Yan
Favorite
1225 - Screening People with Persistent Absolute Lymphocytosis Favors the Identification of High-Count Monoclonal B-Cell Lymphocytosis
XiaoJie Yan
Favorite
1305 - CLECL1⁺ Proliferative CLL Cells Remodel the Lymph Node Microenvironment Through Fibroblast Reprogramming, Th2 Polarization, and M2 Macrophage Induction to Promote Immune Evasion and Disease Progression
XiaoJie Yan
Favorite
Yan, Yuting

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
1015 - Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
Yuting Yan
Favorite
Yan, Yuting

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
1113 - Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis
Yuting Yan
Favorite
1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
Yuting Yan
Favorite
Yan, Yuting

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
1427 - A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL)
Yuting Yan
Favorite
1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
Yuting Yan
Favorite
Yan, Yuting

Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College
2001 - Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
Yuting Yan
Favorite
Yates, Debbie

CLL support Association, UK
1705 - Inequalities in the diagnosis and survival of 30,071 people consecutively diagnosed with chronic lymphocytic leukaemia in England between 2014 and 2021: preliminary analysis from the UNCOVER Study Group
Debbie Yates
Favorite
Yin, Yanping

Oslo University Hospital
1441 - A functional prognostic model predicts progression free survival in patients with relapsed chronic lymphocytic leukemia treated with ibrutinib + venetoclax
Yanping Yin
Favorite
Yi, Shuhua

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
1015 - Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
Shuhua Yi
Favorite
1113 - Stereotyped BCR Subset #8 in Chinese CLL: Molecular Genetics, Clinical Behaviour, and Prognosis
Shuhua Yi
Favorite
1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
Shuhua Yi
Favorite
1427 - A Prospective Multicenter Study of FCR Alternating with Ibrutinib in Treatment-naive Patients with chronic lymphocytic leukemia (CLL)
Shuhua Yi
Favorite
1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
Shuhua Yi
Favorite
2001 - Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
Shuhua Yi
Favorite
Yitzhak, Liron

Tel Aviv Sourasky Medica Center
1903 - Hematopoietic Progenitor Kinase-1 (HPK-1) Inhibition Improves the In Vitro Efficacy of
Bispecific Antibodies in CLL
Liron Yitzhak
Favorite
Yong Jin, Hyun

Genentech Inc., South San Francisco, CA, USA
1104 - A Multi-Gene Expression-Based Prognostic Model for Risk Stratification in Chronic Lymphocytic Leukemia (CLL)
Hyun Yong Jin
Favorite
Yosifov, Deyan

Division of CLL, Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany and German Cancer Research Center (DKFZ), Heidelberg, Germany
1108 - CLL10000: Robust Classification of 1172 ATM Variants employing a Five-Factor Score derived from matched Non-Tumor Controls
Deyan Yosifov
Favorite
1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Deyan Yosifov
Favorite
Yost, Andrielle

The Max Foundation
2003 - Evaluating Gaps and Opportunities in Chronic Lymphocytic Leukemia Treatment Access: Institutional Capacity Assessments in 18 LMICs
Andrielle Yost
Favorite
Young, Marc

Institute of Immunology, Ulm University Hospital, Ulm, Germany
1425 - IGLV3-21R110 as a prognostic marker for early stage CLL patients – clinical implications in patients treated with BTK inhibitors and diagnostic challenges
Marc Young
Favorite
Ysebaert, Loic

IUCT Oncopole
1413 - A fixed-duration, chemo-sparing approach in CLL: 8-year results of the phase 2 ICLL-07 FILO trial
Loic Ysebaert
Favorite
1416 - CLL18 / MOIRAI: an international phase-III trial aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes in first-line treatment of CLL/SLL
Loic Ysebaert
Favorite
1521 - Real-world efficacy and safety of venetoclax +/- rituximab in >75-years old patients or with cardiovascular comorbidities and R/R chronic lymphocytic leukemia: interim results of the VERONE study
Loic Ysebaert
Favorite
1704 - Feasibility of an individualized physical activity Intervention in CLL patients receiving ibrutinib +/-venetoclax: preliminary results from the QOLIBRI Study
Loic Ysebaert
Favorite
Yuan, Bolin

School of Clinical Medicine, Shandong Second Medical University, Weifang, China
1015 - Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
Bolin Yuan
Favorite
Yuan, Dong

BeOne Medicines Ltd
1410 - Impact of testing for genetic markers on treatment selection and clinical outcomes among patients with chronic lymphocytic leukemia
Dong Yuan
Favorite
Yuan, Yaxia

University Of Texas San Antonio
1440 - Transcriptional reprogramming and survival co-dependencies of chronic lymphocytic leukemia resistant to venetoclax
Yaxia Yuan
Favorite
Yuan, Yongyi

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital
1203 - SF3B1 K700E Mutation Promotes SAT1-Mediated Metabolic Reprogramming and Suppresses T-cell Immune Response in Chronic Lymphocytic Leukemia
Yongyi Yuan
Favorite
1802 - Targeting SF3B1 Disrupts Chronic Lymphocytic Leukemia Survival via PFKFB-mediated Glycolytic Dependency
Yongyi Yuan
Favorite
Yu, Eun sang

Division of Hemato-Oncology, Department of Internal Medicine, Korea University Guro Hospital, Korea University College of Medicine
2006 - Understanding the unmet needs in diagnostics and therapeutics of chronic lymphocytic leukemia in Korea
Eun sang Yu
Favorite
Yu, Ka Ka

King's College London
1804 - BRD4 maintains the surface phenotype of Chronic Lymphocytic Leukemia cells
Ka Ka Yu
Favorite
Yu, Lianbo

The Ohio State University
1801 - Targeting BTKi-Resistant CLL Using the Dual Irreversible/Reversible 4th Generation BTK Inhibitor Rocbrutinib
Lianbo Yu
Favorite
Yu, Minjie

Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing Medical University
1008 - Clinical characteristics and outcome of chronic lymphocytic leukemia patients with renal involvement in the era of target drugs
Minjie Yu
Favorite
1431 - The role of Minimal Residual Disease in chronic lymphocytic leukemia
Minjie Yu
Favorite
Yu, Tengteng

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
Tengteng Yu
Favorite
Yu, Ying

1. State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China； 2. Tianjin Institutes of Health Science，Tianjin 301600, China.
1015 - Monoclonal Gammopathy Defines a Distinct Clinical in Chronic Lymphocytic Leukemia Across Therapeutic Eras
Ying Yu
Favorite
1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
Ying Yu
Favorite
1428 - A Prospective, Single-Center, Single-Arm Clinical Trial of Zanubrutinib Monotherapy and ZFCG combined therapy was given sequentially for the Treatment of Primary Symptomatic CLL/SLL (Stop Trial)
Ying Yu
Favorite
2001 - Comparative Analysis of Patients’ Characteristics, Treatment, and Survival Outcomes in CLL from China and the US
Ying Yu
Favorite
Yu, Zhen

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology& Blood Diseases
1119 - MYD88 Mutations in Chronic Lymphocytic Leukemia Exhibit Distinct Biological Behaviors and Prognostic Implications
Zhen Yu
Favorite